HealthDay News — For patients with inadequately controlled, basal insulin-treated type 2 diabetes, a novel, titratable, fixed-ratio combination of insulin glargine (iGlar) and lixisenatide (iGlarLixi) is associated with improvements in glycemic control and reduced body weight, according to a study published in Diabetes Care.
Vanita R. Aroda, MD, from the Medstar Health Research Institute in Hyattsville, Maryland, and colleagues examined the efficacy and safety of iGlarLixi compared with iGlar in patients with type 2 diabetes inadequately controlled on basal insulin with or without up to 2 oral glucose-lowering agents (LixiLan-L; ClinicalTrials.gov identifier: NCT02058160). At total of 736 basal insulin-treated patients were randomly allocated to open-label once-daily iGlarLixi or iGlar.
The researchers found that during the 6-week run-in period there was a decrease in HbA1c from 8.5% to 8.1%. Greater reductions in HbA1c from baseline were seen for iGlarLixi vs iGlar after randomization (−1.1% vs −0.6%; P <.0001), reaching a mean final HbA1c of 6.9% and 7.5% for iGlarLixi and iGlar, respectively. Fifty-five percent and 30% of patients on iGlarLixi and iGlar, respectively, reached a final HbA1c lower than 7.0%. The change in mean body weight was −0.7 kg with iGlarLixi and +0.7 kg with iGlar, respectively (P <.0001).
“iGlarLixi achieved superior improvements in glycemic control, with beneficial effects on body weight, no additional risk of hypoglycemia compared with iGlar, and a low rate of gastrointestinal adverse effects,” the researchers wrote.
Disclosures: This study was sponsored by Sanofi.
- Aroda VR, Rosenstock J, Wysham C, et al; for the LixiLan-L Trial Investigators. Efficacy and safety of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin: The LixiLan-L randomized trial [published online September 20, 2016]. Diabetes Care. doi:10.2337/dc16-1495.